Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ishita Drugs and Industries Limited specializes in the manufacturing of pharmaceutical products, primarily focusing on active pharmaceutical ingredients (APIs) and formulations. The company operates primarily in India and has a competitive edge due to its low debt levels and strong current ratio, which provides financial stability in a volatile market.
Ishita Drugs generates revenue through the production and sale of APIs and finished pharmaceutical formulations. The company benefits from a low-cost manufacturing model and a strong distribution network in India, which allows it to maintain competitive pricing and secure contracts with local and international clients.
Changes in regulatory policies affecting pharmaceutical manufacturing in India
Fluctuations in raw material costs for APIs
Market demand for generic drugs in emerging markets
Partnerships or contracts with larger pharmaceutical companies
Regulatory changes impacting drug approval processes
Technological advancements in drug manufacturing that could render current processes obsolete
Increased competition from generic drug manufacturers
Pricing pressures from larger pharmaceutical companies
Low revenue growth may limit cash flow generation
Potential liquidity issues if operational cash flow does not improve
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand can be affected by consumer spending on healthcare.
Low - With a debt/equity ratio of 0.01, interest rates have minimal impact on financing costs, but rising rates could affect consumer spending on pharmaceuticals.
minimal - The company has low debt levels, reducing its exposure to credit conditions.
value - Investors may be drawn to the company's low debt and current ratio, indicating financial stability despite recent revenue declines.
low - The company's low debt levels and stable cash flow suggest lower volatility compared to peers.
